Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2015)
12 slides from Patrys's shareholder meeting presentation, Nov 11, 2015
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Dr James Campbell, CEO 11 November 2015 ASX: PAB
Slide 2: Safe Harbour Statement
Safe Harbour Statement For personal use only This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Patrys Limited to be materially different
Slide 3: Year in Review
Year in Review Challenges For personal use only o PAT-SM6 manufacturing difficulties o Clinical trial deferral o CAR T cell program discontinued Developments o Board of Directors unified in its commitment to rebuilding shareholder value o Appointed experienced CEO o Completed Chinese licensing deal
Slide 4: Experienced & Capable Team
Experienced & Capable Team For personal use only John Read Chairman James Campbell CEO & Managing Director Mike Stork Non-Executive Director Suzy Jones Non-Executive Director Melanie Leydin CFO & Company Secretary Deanne Greenwood VP, Business Development & IP Valentina Dubljevic VP, Scientific & Cl
Slide 5: Pipeline
Pipeline For personal use only Product Discovery Preclinical Phase I Phase 2a (Target) PAT-SM6 Ongoing Multiple Myeloma Combination Therapy (GRP78) development PAT-SC1 Gastric Cancer Partnered in (CD55) China PAT-LM1 Partnering Solid Tumours (NONO) opportunity PAT-SM3 Co-development PAT-SM4 opportun
Slide 6: PAT-SM6
PAT-SM6 For personal use only o Completed Phase I/IIa clinical trial in multiple myeloma in Dec 2013 o 33% of treated patients showing evidence of stable o well tolerated with no SAEs or dose limited toxicities reported, no evidence of immunogenicity o Positive results in patient in combination with
Slide 7: Chimeric Antigen Receptor (CAR) T Cell Program
Chimeric Antigen Receptor (CAR) T Cell Program For personal use only o CAR T feasibility studies performed by a European development company completed o Development team agreed to discontinue this collaboration which had the potential to produce targeted and potent therapies against cancer cells o W
Slide 8: Looking Ahead
Looking Ahead For personal use only o Patrys is a biologicals company focused on the discovery and development of new antibody therapies to treat cancer and improve patient outcomes o Patrys’ was founded on the IgM platform, which has generated several exciting lead candidates that in human studies
Slide 9: Business Development
Business Development For personal use only o Patrys has recently completed the out-licensing agreement for PAT- SC1 with the integrated Chinese drug development company, Hefei Co-source o Exclusive development and commercialisation rights for all oncology indications in China for PAT-SC1 o Financial
Slide 10: Completing the Transformation
Completing the Transformation For personal use only o Patrys’ Board and Management are focused on rebuilding shareholder value o Corporate restructuring has dramatically reduced the cost base o Partnerships and non-dilutive cash are actively being pursued to cost-effectively progress asset developme
Slide 11: The Year Ahead
The Year Ahead For personal use only o Decisions on the manufacturing and clinical development of PAT-SM6 o Multiple co-development alliances for early stage IgM assets o Active in-licensing/acquisition efforts for complementary assets o Re-engagement with shareholders 11 Annual General Meeting Nove
Slide 12: For Further Information
For personal use only For Further Information Contact Details: Dr. James Campbell, CEO and Managing Director Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com